ROIVANT SCIENCES LTD. Shareholders' Equity
ROIVANT SCIENCES LTD. (ROIV) had Shareholders' Equity of $4.23 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $4.23B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $4.53B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $4.27B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $4.36B.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $4.23B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.53B 10-Q · filed 2026-08-06 |
| 2025-12-31 | $4.27B 10-Q · filed 2026-02-06 |
| 2025-09-30 | $4.36B 10-Q · filed 2025-11-10 |
| 2025-06-30 | $4.35B 10-Q · filed 2025-08-11 |
| 2025-03-31 | $4.69B 10-K · filed 2026-05-20 |
| 2024-12-31 | $5.19B 10-Q · filed 2025-02-10 |
| 2024-09-30 | $5.15B 10-Q · filed 2024-11-12 |
| 2024-06-30 | $5.44B 10-Q · filed 2024-08-09 |
| 2024-03-31 | $5.97B 10-K · filed 2025-05-29 |
| 2023-12-31 | $6.09B 10-Q · filed 2024-02-13 |
| 2023-09-30 | $948.53M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $910.73M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.16B 10-K · filed 2024-05-30 |
| 2022-12-31 | $955.52M 10-Q · filed 2023-02-13 |
| 2022-09-30 | $1.16B 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.38B 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.66B 10-K · filed 2023-06-28 |
| 2021-12-31 | $1.87B 10-Q · filed 2022-02-14 |
| 2021-09-30 | $2.04B 10-Q · filed 2021-11-15 |
| 2021-06-30 | $1.72B 10-Q · filed 2021-09-21 |
| 2021-03-31 | $1.80B 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |